Canakinumab (Ilaris) is an important biological agent. As an interleukin-1β (IL-1β) blocker, it has extensive clinical application value.

What Are the Indications for Canakinumab (Ilaris)?

Cryopyrin-Associated Periodic Syndromes (CAPS)

Applicable Population: Adult patients and pediatric patients aged 4 years and above.

Specific Disease Types: Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).

Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS)

Treatment Population: Adult and pediatric patients.

Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency (HIDS/MKD), which is applicable to both adult and pediatric patient populations.

Familial Mediterranean Fever (FMF)

It is also suitable for patients of all ages, including adults and children.

Still's Disease

Adult-Onset Still’s Disease (AOSD).

Systemic Juvenile Idiopathic Arthritis (SJIA).

Minimum Applicable Age: Patients aged 2 years and above.

Weight Requirement: Patients must have a body weight of 7.5 kg or more.

Gout Flares

Specifically indicated for adult gout patients who meet certain conditions: those with contraindications to, intolerance of, or inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine, and for whom repeated courses of corticosteroids are inappropriate.

Specifications and Properties of Canakinumab (Ilaris)

Basic Physical Characteristics

Dosage Form: Injection.

Concentration: 150mg/mL solution.

Appearance: Clear to slightly opalescent, colorless to slightly yellowish-brown solution.

Packaging Form

Single-dose vial packaging.

Each vial has a volume of 1mL, containing 150mg of canakinumab.

Composition

Active Ingredient: Canakinumab.

Excipients: L-histidine (2.1mg), L-histidine hydrochloride monohydrate (1.3mg), mannitol (49.2mg), polysorbate 80 (0.4mg), and sterile water for injection.

Storage and Handling Methods for Canakinumab (Ilaris)

Storage Requirements

Temperature Control: Must be stored in a refrigerated environment at 2°C to 8°C (36°F to 46°F).

Light Protection: Keep in the original carton to protect from light exposure.

Prohibition of Freezing: Do not store in a frozen environment.

Precautions for Use

Normal State: Essentially particle-free, clear to opalescent, colorless to slightly yellowish-brown.

Handling of Abnormal State: Discard if significant brown discoloration occurs.

Do not use if there is marked opalescence or visible particles.

Avoid Shaking: Do not shake the vial vigorously.

Waste Disposal

Residue Handling: Unused product in single-dose vials should be disposed of in accordance with local requirements.

Expiry Date Management

Do not use the drug after the date printed on the label.